First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.

Clin Transl Sci · 2022 · PMC8841437 · PMID 34558200

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

After SADs and MADs of milvexian, there was a clear trend that aPTT was prolonged, and the magnitude of change was related to drug exposure (Figure S1 a; see Figure 2 for drug exposure).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.